Market Cap 81.17M
Revenue (ttm) 180,000.00
Net Income (ttm) -9.54M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -5,300.00%
Debt to Equity Ratio 0.00
Volume 374,036
Avg Vol 169,306
Day's Range N/A - N/A
Shares Out 45.86M
Stochastic %K 26%
Beta 1.71
Analysts Sell
Price Target $10.00

Company Profile

Entera Bio Ltd., a clinical stage company, focuses on developing oral peptide or protein replacement therapies for unmet medical needs. The company leverages its N-Tab platform that is designed to simultaneously stabilize the peptide in the gastrointestinal tract and promote its absorption into the bloodstream. It also develops EB613, an oral PTH (1-34), that has completed Phase 2 clinical trial for the treatment of post-menopausal women with low bone mineral density and high-risk osteoporosis;...

Industry: Biotechnology
Sector: Healthcare
Phone: 972 2 532 7151
Address:
Kiryat Hadassah Minrav Building, Fifth Floor, Jerusalem, Israel
TrevPhil13
TrevPhil13 Dec. 23 at 1:50 PM
$ENTX Lots of good news!
0 · Reply
WallStWireAds
WallStWireAds Dec. 23 at 1:33 PM
$ENTX https://caplynx.io/A9EAG8N
0 · Reply
DARKP00L
DARKP00L Dec. 22 at 1:55 PM
$ENTX 08:33 on Dec. 22 2025 Entera Bio Announces New Validating In Vivo Pharmacokinetic And Pharmacodynamic Data That Supports Development Of Proprietary Long-Acting PTH Analog Using N-Tab Platform For Patients With Hypoparathyroidism #tradeideas
0 · Reply
WallStWireAds
WallStWireAds Dec. 22 at 1:31 PM
$ENTX https://caplynx.io/Dv6OGIU
0 · Reply
TrevPhil13
TrevPhil13 Dec. 19 at 6:58 PM
0 · Reply
NVDAMillionaire
NVDAMillionaire Dec. 19 at 8:23 AM
$ENTX Brilliant piece that captures ENTX's situation perfectly. So if you want to update your understanding of ENTX or get to know ENTX better, this is essential reading. https://beyondspx.com/quote/ENTX/analysis/entx-oral-biologics-promise-meets-funding-reality-at-2-06
0 · Reply
TrevPhil13
TrevPhil13 Dec. 17 at 2:58 PM
$ENTX Just a matter of time for this market disruptive product like this. If you listen to her interviews and listen to current research leaders. They are definitely trying to focus on bone improvements earlier and life and the use of anabolic medications such as EB613.
0 · Reply
Sumit56
Sumit56 Dec. 16 at 6:04 PM
$ENTX Santa Claus rally coming for Entera
0 · Reply
WallStWireAds
WallStWireAds Dec. 16 at 3:53 PM
$ENTX https://thefinanceherald.com/this-under-the-radar-biotech-microcap-is-taking-aim-at-one-of-healthcares-biggest-unmet-needs-nasdaq-entx/
1 · Reply
TheRealShortSqueezy
TheRealShortSqueezy Dec. 15 at 8:12 PM
📈 $HYFT: Chart Starting to Tell a New Story This morning’s earnings delivered record revenue growth, expanding margins, and major AI-pipeline progress, setting the tone for today’s strong price action. 🔥 Technical Highlights Powerful intraday move from $1.77 → $2.09 highs, confirming aggressive buyer interest 1️⃣ Healthy consolidation in the $1.85–$1.95 range 2️⃣Higher lows forming, showing steady accumulation on dips 3️⃣ Surging volume on the breakout, validating the move with real demand 4️⃣ Retesting the breakout zone as support, a constructive bullish pattern If $HYFT clears $2 with momentum, the next targets stack up at: $2.16 ➡️$2.31 ➡️ $2.50 ➡️ $2.75 ➡️ $2.92 ➡️ $3.26 With recent milestones and major catalysts ahead, HYFT is well positioned to tap into a fast growing multi-billion dollar AI-biotech market. Communicated Disclaimer : https://tinyurl.com/58pvrf5j Sector Peers: $CRSP $ABCL $ONC $ENTX
0 · Reply
Latest News on ENTX
Entera Bio to Participate in Upcoming Events

Feb 24, 2025, 8:30 AM EST - 10 months ago

Entera Bio to Participate in Upcoming Events


Entera Bio to Participate in Upcoming Investor Conferences

Sep 5, 2023, 8:00 AM EDT - 2 years ago

Entera Bio to Participate in Upcoming Investor Conferences


Entera Bio Regains Compliance with Nasdaq Listing Requirements

Mar 23, 2023, 9:27 AM EDT - 2 years ago

Entera Bio Regains Compliance with Nasdaq Listing Requirements


TrevPhil13
TrevPhil13 Dec. 23 at 1:50 PM
$ENTX Lots of good news!
0 · Reply
WallStWireAds
WallStWireAds Dec. 23 at 1:33 PM
$ENTX https://caplynx.io/A9EAG8N
0 · Reply
DARKP00L
DARKP00L Dec. 22 at 1:55 PM
$ENTX 08:33 on Dec. 22 2025 Entera Bio Announces New Validating In Vivo Pharmacokinetic And Pharmacodynamic Data That Supports Development Of Proprietary Long-Acting PTH Analog Using N-Tab Platform For Patients With Hypoparathyroidism #tradeideas
0 · Reply
WallStWireAds
WallStWireAds Dec. 22 at 1:31 PM
$ENTX https://caplynx.io/Dv6OGIU
0 · Reply
TrevPhil13
TrevPhil13 Dec. 19 at 6:58 PM
0 · Reply
NVDAMillionaire
NVDAMillionaire Dec. 19 at 8:23 AM
$ENTX Brilliant piece that captures ENTX's situation perfectly. So if you want to update your understanding of ENTX or get to know ENTX better, this is essential reading. https://beyondspx.com/quote/ENTX/analysis/entx-oral-biologics-promise-meets-funding-reality-at-2-06
0 · Reply
TrevPhil13
TrevPhil13 Dec. 17 at 2:58 PM
$ENTX Just a matter of time for this market disruptive product like this. If you listen to her interviews and listen to current research leaders. They are definitely trying to focus on bone improvements earlier and life and the use of anabolic medications such as EB613.
0 · Reply
Sumit56
Sumit56 Dec. 16 at 6:04 PM
$ENTX Santa Claus rally coming for Entera
0 · Reply
WallStWireAds
WallStWireAds Dec. 16 at 3:53 PM
$ENTX https://thefinanceherald.com/this-under-the-radar-biotech-microcap-is-taking-aim-at-one-of-healthcares-biggest-unmet-needs-nasdaq-entx/
1 · Reply
TheRealShortSqueezy
TheRealShortSqueezy Dec. 15 at 8:12 PM
📈 $HYFT: Chart Starting to Tell a New Story This morning’s earnings delivered record revenue growth, expanding margins, and major AI-pipeline progress, setting the tone for today’s strong price action. 🔥 Technical Highlights Powerful intraday move from $1.77 → $2.09 highs, confirming aggressive buyer interest 1️⃣ Healthy consolidation in the $1.85–$1.95 range 2️⃣Higher lows forming, showing steady accumulation on dips 3️⃣ Surging volume on the breakout, validating the move with real demand 4️⃣ Retesting the breakout zone as support, a constructive bullish pattern If $HYFT clears $2 with momentum, the next targets stack up at: $2.16 ➡️$2.31 ➡️ $2.50 ➡️ $2.75 ➡️ $2.92 ➡️ $3.26 With recent milestones and major catalysts ahead, HYFT is well positioned to tap into a fast growing multi-billion dollar AI-biotech market. Communicated Disclaimer : https://tinyurl.com/58pvrf5j Sector Peers: $CRSP $ABCL $ONC $ENTX
0 · Reply
TheRealShortSqueezy
TheRealShortSqueezy Dec. 15 at 1:47 PM
$HYFT: RECORD Growth + Big Pipeline Wins Just Dropped 🗞️📰 MindWalk Holdings Corp just delivered its strongest quarter yet, combining major financial momentum with breakthrough AI driven pipeline progress. 📈 Financial Highlights: ➖ Revenue $4.1M (+54% YoY, +30% QoQ) ➖Gross margin 65% (up from 51%) ➖Gross profit +94% YoY ➖ $16.5M cash for platform + pipeline expansion 🧬 Pipeline Highlights: ➖ GLP-1: AI-designed agonist outperforming semaglutide ➖ Added longevity pathway → dual-pathway metabolic program 💥 Strategic Progress: ➖ Rebrand completed + new CFO/CBO ➖ Netherlands sale → $14.3M redirected to AI + wet lab programs 🔥 Next Catalyst: ➖ Mid-January pipeline + partnership update at JPM Healthcare Conference Record growth, stronger margins, and a loaded pipeline, $HYFT’s momentum is accelerating fast. Communicated Disclaimer : https://tinyurl.com/58pvrf5j Sector Peers: $IGMS $ANTX $CABA $ENTX
0 · Reply
TheRealShortSqueezy
TheRealShortSqueezy Dec. 15 at 1:05 PM
$HYFT: The Quiet Innovator That’s About to Get Loud 🔊 MindWalk Holdings is an AI driven biotech using its HYFT and LensAI platforms to disrupt a drug discovery market set to surge from $1.5B to $20B+ by 2030. Major Milestones 🔥 ➡Strategic rebrand + pivot into AI driven drug discovery ➡Revenue growth with narrowing losses ➡HYFT + LensAI gaining traction for speeding drug design Upcoming Catalysts ⚡ ➡Conference/earnings call today, any positive updates can spark fresh interest ➡Potential new platform updates ➡High-value partnership opportunities ➡Sector tailwinds from AI-biotech adoption Analyst Price Targets: 🎯Analysts sit around $3$5, suggesting notable upside. HYFT is helping shape the future of drug discovery, and the market is only beginning to catch on. Communicated Disclaimer : https://tinyurl.com/58pvrf5j Sector Peers: $CRSP $ABCL $ONC $ENTX
3 · Reply
Ggeetz
Ggeetz Dec. 12 at 2:07 AM
$ENTX Now its time to get back to 3$
0 · Reply
TrevPhil13
TrevPhil13 Dec. 11 at 8:40 PM
$ENTX There we go!
0 · Reply
Stringy51
Stringy51 Dec. 10 at 7:19 PM
$ENTX good fed news! Time to take off!?!
0 · Reply
TrevPhil13
TrevPhil13 Dec. 9 at 2:48 PM
$ENTX There isn't any reason it should take off this week. Anyone get transcription of recent interview at Evercore event?
0 · Reply
Sumit56
Sumit56 Dec. 8 at 5:08 PM
$ENTX With all this momentum, any clue what’s holding this thing down?
0 · Reply
Stringy51
Stringy51 Dec. 8 at 4:01 AM
$ENTX We going to get nice uptick this week assuming fed rate cut?
1 · Reply
Ggeetz
Ggeetz Dec. 6 at 4:56 AM
0 · Reply
Sumit56
Sumit56 Dec. 4 at 5:11 PM
$ENTX I get the feeling tomorrow is the day ENTX blows through the resistance that it’s getting here and really gets on some big money radars.
1 · Reply
Sumit56
Sumit56 Dec. 4 at 3:05 PM
$ENTX Hard not to with the recent news.
0 · Reply
TrevPhil13
TrevPhil13 Dec. 4 at 2:12 PM
$ENTX Adding shares at this cost!
0 · Reply